Sector News

AstraZeneca spins off autoimmune drugs into new biotech company

March 1, 2018
Life sciences

AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.

The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer.

Chief Executive Pascal Soriot said earlier this month that AstraZeneca had a drug pipeline that was “over-sized relative to the current size of our company”.

It has already divested a number of medicines in recent years. In 2017, so-called externalization deals, involving asset sales and partnerships, contributed $2.3 billion out of total revenue of $22.5 billion, prompting criticism from some analysts who argue such transactions unduly flatter results.

In the case of the new inflammation and autoimmunity company, called Viela Bio, AstraZeneca will retain a significant interest as the new company’s largest minority shareholder.

Viela Bio’s potential new medicines include inebilizumab for neuromyelitis optica, a rare disease affecting the optic nerve and spinal cord of around five in 100,000 people. The drug has orphan drug status and could be filed for approval in late 2019 or early 2020.

However, the deal does not include anifrolumab, a promising treatment in final-stage clinical testing that AstraZeneca is developing for lupus, an chronic autoimmune disease with limited treatment options.

Bahija Jallal, head of AstraZeneca’s MedImmune biotech unit, said the drugmaker would remain strongly active in immunology. “Our strategy is very much to follow the science. In some cases, we will develop the science in-house and in other cases it will be developed elsewhere,” she said in a phone interview.

Viela Bio will be based in Gaithersburg, Maryland, and will be funded with $250 million from a consortium of investors led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital.

The new company’s chief executive is Bing Yao, currently head of respiratory, inflammation and autoimmunity at AstraZeneca’s MedImmune innovative medicines unit. Several other MedImmune staff will also move across to the new business, including Jorn Drappa, who will head up research.

It is not the first time AstraZeneca has shifted assets into a new biotech company in this way. In 2015, it spun out its early small-molecule anti-infective drugs into Entasis Therapeutics and in 2008 it shifted gastrointestinal research into a company called Albireo.

By Ben Hirschler

Source: Reuters

comments closed

Related News

May 10, 2025

FDA approves Teal Health HPV screening test as an at-home alternative to the Pap smear

Life sciences

According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.

May 10, 2025

FDA appoints first chief AI officer as it looks to speed up reviews

Life sciences

Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.

May 10, 2025

Roquette announces a new organization following the acquisition of IFF Pharma Solutions

Life sciences

The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.

How can we help you?

We're easy to reach